Duyuru • Feb 11
Venus Concept Inc.(NasdaqCM:VERO) dropped from S&P TMI Index Venus Concept Inc.(NasdaqCM:VERO) dropped from S&P TMI Index Duyuru • Feb 09
Venus Concept Inc. Files Form 15 Venus Concept Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share. Duyuru • Jan 23
Venus Concept Inc. Approves A Plan to Voluntarily Delist the Company's Common Stock from the Nasdaq Capital Market On January 20, 2026, the Board of Directors of Venus Concept Inc. approved a plan to voluntarily delist the Company's common stock from the Nasdaq Capital Market (Nasdaq"), suspend its duty to file periodic reports and other information with the U.S. Securities and Exchange Commission (SEC"), and terminate its registration of common stock under U.S. federal securities laws. The Company intends to file a Notification of Removal from Listing and/or Registration on Form 25 with the SEC on or about January 30, 2026, to effect the voluntary withdrawal of the listing of its securities from Nasdaq and the deregistration of its securities under Section 12(b) of the Securities and Exchange Act of 1934, as amended (the Exchange Act"). The Company anticipates that the delisting from Nasdaq and deregistration under Section 12(b) of its securities will become effective on or about February 6, 2026, at which time trading on Nasdaq will cease. Following the effectiveness of the Form 25, the Company intends to file a Form 15 with the SEC to suspend its reporting obligations under Section 15(d) of the Exchange Act, at which time the Company anticipates that its obligation to file periodic reports under the Exchange Act, including annual, quarterly and current reports on Form 10-K, Form 10-Q and Form 8-K, respectively, will be suspended, and that all requirements associated with being an Exchange Act-registered company, including the requirement to file current and periodic reports, will terminate permanently 90 days thereafter. The decision to voluntarily delist was made after careful consideration of several factors, including costs associated with being a public reporting company, low trading volumes, regulatory burdens, and to better focus the Company's resources on enhancing long-term stockholder value. The Company expects to realize meaningful savings on an annual basis as a result of the delisting and deregistering of the Company's common stock. New Risk • Jan 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 57% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Share price has been highly volatile over the past 3 months (57% average daily change). Shareholders have been substantially diluted in the past year (182% increase in shares outstanding). Market cap is less than US$10m (US$2.66m market cap). New Risk • Dec 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Shareholders have been substantially diluted in the past year (182% increase in shares outstanding). Market cap is less than US$10m (US$3.10m market cap). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Board Change • Dec 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Member of Advisory Board Eric Bernstein was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Nov 11
Venus Concept Inc. Receives 510(K) for the Venus NOVA, Its Most Advanced Multi- Application Platform for Non-Invasive Body and Skin Treatments Venus Concept Inc. announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market the Venus NOVA™, the Company's next-generation multi-application platform designed to redefine non-invasive treatments for the body, face, and skin. Venus NOVA integrates Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)2 combining Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™? technology -delivering a powerful, comprehensive solution for body contouring, muscle conditioning, skin treatments, and wrinkle and cellulite reduction. Venus NOVA reflects the evolution of Venus Concept's commitment to science-based innovation, intelligent technology, and practice growth. With built-in IoT connectivity through Venus Connect™, a secure cloud-based application, clinics gain access to real-time analytics, treatment insights, and automatic system optimization to enhance efficiency and profitability. Key innovations include: FlexMAX EMS: Dual-electrode design delivering adaptive electrical stimulation to safely activate up to 8 muscle groups with up to 100,000 contractions per session. 4D Body, OctiPolar™, and DiamondPolar™? Applicators: Ergonomically designed for precision, comfort, and versatility across body and facial applications. (MP)2: Proprietary combination of Multi-Polar RF and PEMF that promotes collagen renewal and improves overall skin appearance. Advanced VariPulse™: Adjustable suction with positive and negative pressure to enhance RF delivery, improve circulation, and support smoother contours. Automatic Temperature Control (ATC): Real-time monitoring and " cruise-control" for maintaining optimal temperature for consistent, comfortable, and effective treatments. Turnkey Integration and Support: Venus NOVA is supported by the Venus Jumpstart Program, a 30-day roadmap providing advanced clinical education, marketing enablement, and strategic implementation. This ensures seamless integration into existing practices and accelerates business success from day one. Availability: Venus NOVA will be available to customers in the United States in December 2025, with global rollouts planned throughout 2026 and beyond. Duyuru • Oct 02
Venus Concept Inc. to Report Q3, 2025 Results on Nov 13, 2025 Venus Concept Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025 Duyuru • Jul 16
Venus Concept Inc. to Report Q2, 2025 Results on Aug 14, 2025 Venus Concept Inc. announced that they will report Q2, 2025 results After-Market on Aug 14, 2025 Duyuru • Jun 12
Madryn Asset Management Engages in Discussions with Venus Concept On June 11, 2025, Madryn Asset Management, LP announced that it has engaged and intend to continue engaging in discussions with management or the board of directors of Venus Concept about its business, operations, strategy, plans and prospects. In addition, without limitation, the Reporting Persons have engaged and intend to continue engaging in discussions with management, the board of directors of the Company, stockholders or other securityholders of or lenders to the Company and other relevant parties or take other actions concerning the offering and sale of securities by the Company or other financing transactions by the Company, any extraordinary corporate transaction, a sale or transfer of a material amount of assets, a change in the board of directors or management, a material change in the capitalization or dividend policies, other material changes in the Company's business or corporate structure, changes in the Company's charter, bylaws or other actions that may impede the acquisition of control, de-listing or de-registration of the Company, or similar actions. Duyuru • Jun 10
Venus Concept Inc. has completed a Follow-on Equity Offering in the amount of $1.152008 million. Venus Concept Inc. has completed a Follow-on Equity Offering in the amount of $1.152008 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 434,720
Price\Range: $2.65
Discount Per Security: $0.186
Transaction Features: Registered Direct Offering Duyuru • Apr 17
Venus Concept Inc., Annual General Meeting, Jun 26, 2025 Venus Concept Inc., Annual General Meeting, Jun 26, 2025. Duyuru • Apr 15
Venus Concept Inc. has completed a Follow-on Equity Offering in the amount of $1.570002 million. Venus Concept Inc. has completed a Follow-on Equity Offering in the amount of $1.570002 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 386,700
Price\Range: $4.06
Discount Per Security: $0.3248
Transaction Features: Registered Direct Offering Duyuru • Apr 10
Venus Concept Inc. has filed a Follow-on Equity Offering in the amount of $1.150006 million. Venus Concept Inc. has filed a Follow-on Equity Offering in the amount of $1.150006 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 328,573
Price\Range: $3.5
Discount Per Security: $0.245
Transaction Features: Registered Direct Offering Duyuru • Apr 07
Venus Concept Inc. to Report Q1, 2025 Results on May 15, 2025 Venus Concept Inc. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025 Duyuru • Mar 04
Venus Concept Inc. to Report Q4, 2024 Results on Mar 31, 2025 Venus Concept Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 31, 2025 Duyuru • Feb 28
Venus Concept Announces Reverse Stock Split to Regain Nasdaq Listing Compliance Venus Concept Inc. announced that it will effect a 1-for-11 reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Stock Split”). The Company’s stockholders previously approved the Reverse Stock Split at a special meeting of stockholders held on February 14, 2025 at a ratio ranging from 1-for-5 up to a ratio of 1-for-16, such ratio and the implementation and timing of such Reverse Stock Split is to be determined by the Company’s Board of Directors at its discretion. The principal purpose of the Reverse Stock Split is to increase the bid price of the Company’s common stock to regain compliance with the continued listing requirements of the Nasdaq Capital Market. Duyuru • Feb 25
Venus Concept Inc. Announces Senior Management Changes Venus Concept Inc. announced several changes to its senior leadership team. Dr. Hemanth Varghese, President and COO will depart the company to pursue other opportunities, effective March 28, 2025, and Bill McGrail, EVP, Technical Operations & Compliance, will retire, effective February 28, 2025. The Company expresses their gratitude for their contribution to Venus’ turnaround and drive for operational excellence globally. With the departures, Kirk Gunhus has been appointed Chief Revenue Officer, with global responsibility for Venus’ sales efforts. This includes oversight of the direct field force, distributor relationships and technical support for all customers. Ross Portaro has been appointed as EVP, Commercial Strategy and Head of Venus Hair, with a focus on providing commercial guidance and expanding Venus Hair business in all jurisdictions. Venus Concept also welcomes back Melissa Kang, the Company’s former EVP, Global Marketing & Product Management, as Chief Product Officer. She will work on continuing the history of innovation at the Company, by guiding future product vision and roadmap. Michael Mandarello, the Company’s Chief Legal Officer, will take on an expanded role as Head of Strategy & Operations, to include oversight of Venus’ corporate strategy and operational execution. These changes are part of Venus Concept’s ongoing transformation efforts and are focused on establishing the optimal senior management structure for the next phase of its evolution. Duyuru • Dec 04
Venus Concept Inc. Announces Resignation of Garheng Kong from Board of Directors and Nominating and Corporate Governance Committee On December 2, 2024, Garheng Kong, M.D. resigned from the Venus Concept Inc.’s board of directors and the Nominating and Corporate Governance Committee of the Company’s board of directors on which he served. The resignation was not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Duyuru • Nov 13
Venus Concept Inc. Provides Earnings Guidance for the Three Months Ending December 31, 2024 Venus Concept Inc. provided earnings guidance for the three months ending December 31, 2024. For the period, Company expects total revenue of at least $17.0 million, representing a 6% decline year-over-year and a 13% increase quarter-over-quarter. Duyuru • Sep 18
Venus Concept Inc. Announces Australian Regulatory Approval for Venus Bliss MAX Venus Concept Inc. announced that it has clearance from the Therapeutic Goods Administration (TGA) in Australia to market the Venus Bliss MAX system. The Venus Bliss MAX is the Company’s platform that offers a comprehensive, world-class solution for all customers’ body treatment needs and is currently available in select markets globally. Featuring three of Venus Concept’s market leading technologies in one, the Venus Bliss MAX is a body shaping solution consisting of proprietary (MP)2 applicator that combines Multi-Polar Radio Frequency with Pulsed Electro Magnetic Fields and advanced VariPulse™ technology for Cellulite Reduction and Skin treatments, Venus’ FlexMax EMS applicators for Muscle Conditioning and a diode laser for Fat Reduction treatments. Duyuru • Aug 14
Venus Concept Inc. Provides Revenue Guidance for the Three Months Ending September 30, 2024 Venus Concept Inc. provided revenue guidance for the three months ending September 30, 2024. For the period, the company expects total revenue to be at least $17.0 million, representing a 3% decline year-over-year and a 3% increase quarter-over-quarter. Duyuru • Jul 29
Venus Concept Inc. Announces Regulatory Approval for Venus Bliss MAX in Canada Venus Concept Inc. announced that it has received a medical device license issued by Health Canada to market the Venus Bliss MAX system in Canada. The Venus Bliss MAX was first available in the United States in early 2022 and subsequently offered in approved jurisdictions around the world. The Venus Bliss MAX is a 3-in-1 body shaping solution featuring three of Venus Concept’s market leading technologies in one complete platform, including diode laser for Fat Reduction treatments, the proprietary (MP)2 applicator that combines Multi-Polar Radio Frequency with Pulsed Electro Magnetic Fields and advanced VariPulse™ technology for Cellulite Reduction and Skin treatments, and the Company’s FlexMax EMS applicators for Muscle Toning and Conditioning. Duyuru • Jul 16
Venus Concept Inc. to Report Q2, 2024 Results on Aug 13, 2024 Venus Concept Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024 Duyuru • May 16
Venus Concept Inc. Provides Earnings Guidance for the Three Months Ending June 30, 2024 Venus Concept Inc. provided earnings guidance for the three months ending June 30, 2024. For the period, the company expects total revenue of at least $16.5 million. Duyuru • May 08
Madryn Asset Management Delivers a Nonbinding Transaction Proposal to Venus Concept On May 7, 2024, Madryn Asset Management, LP announced that on May 3, 2024, it has delivered a nonbinding transaction proposal to Venus Concept Inc. concerning a proposed restructuring of the Company’s current debt and equity capital structure. Pursuant to the proposal, Madryn Asset Management would exchange a portion of Main Street Lending Program loan and/or other debt instruments held by Madryn Asset Management for common stock, in addition to entering into a new senior secured credit facility as a part of a comprehensive restructuring of the Company’s outstanding debt. Madryn Asset Management stated that as a result of the transactions contemplated by the proposal, Madryn Asset Management would become the majority owners of the Company’s common stock on a fully diluted basis. Duyuru • May 01
Venus Concept Inc., Annual General Meeting, Jun 05, 2024 Venus Concept Inc., Annual General Meeting, Jun 05, 2024, at 08:30 US Eastern Standard Time. Agenda: To consider and approve the election of Directors; to consider and approve the MNP LLP as the independent accounting firm; and to consider and approve any other matters. Duyuru • Apr 18
Venus Concept Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement as Required for Continued Listing Under Listing Rule 5550(a)(2) On April 11, 2024, Venus Concept Inc. (the ‘Company’) received a notice (the ‘Notice’) from the Listing Qualifications Department (the ‘Staff’) of the Nasdaq Stock Market (‘Nasdaq’) stating that for 32 consecutive business days the Company’s common stock (the ‘Common Stock’) did not maintain a minimum closing bid price of $1.00 per share (‘Minimum Bid Price Requirement’) as required for continued listing under Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Common Stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until October 8, 2024, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days before October 8, 2024, at which time the Staff will provide written notification to the Company that it complies with the Minimum Bid Requirement, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Common Stock does not achieve compliance by October 8, 2024, the Company may be eligible for an additional 180-day period to regain compliance, provided that it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, for example, by effecting a reverse stock split, if necessary. The Company intends to actively monitor the closing bid price of the Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules. Duyuru • Apr 16
Venus Concept Inc. to Report Q1, 2024 Results on May 15, 2024 Venus Concept Inc. announced that they will report Q1, 2024 results Pre-Market on May 15, 2024 Duyuru • Apr 09
Venus Concept Inc. Announces Israeli Regulatory Approval for Venus Bliss MAX Venus Concept Inc. announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus Bliss MAX was first launched commercially in the United States in First Quarter 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions. The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 application that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse technology and the Company's FlexMax EMS applicators. This advanced three-in-one platform enables practitioners to offer treatments for non-invasive lipolysis of the abdomen, flanks, back, and thighs, relief of muscle aches and pain, relief of muscle spasms, improvement in blood circulation, reduction in the appearance of cellulite and for muscle conditioning to stimulate healthy muscles. Duyuru • Apr 03
Venus Concept Inc. Provides Earning Guidance for the Three Months Ended March 31, 2024 Venus Concept Inc. provided earning guidance for the three months ended March 31, 2024. For the three months the Company expects total revenue of at least $16.5 million. Duyuru • Mar 26
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules Venus Concept Inc. announced that it received a decision from the Nasdaq Hearings Panel (the ‘Nasdaq Panel’) granting its request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) or any of the alternative requirements under Nasdaq Listing Rule 5550(b) on or before May 28, 2024, and certain other conditions (the ‘Panel Decision’). On May 31, 2023, Nasdaq Listing Qualifications staff (‘Nasdaq Staff’) issued the Company a deficiency notice citing that the stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing under Nasdaq Listing Rule 5550(b)(1) (‘Minimum Equity Requirement’). On July 17, 2023, the Company submitted to the Nasdaq Staff a plan to regain compliance with the Minimum Equity Requirement (the ‘Plan’). On July 28, 2023, the Nasdaq Staff granted an extension until November 27, 2023 to evidence compliance with the Minimum Equity Requirement, conditioned upon the Company’s achievement of certain milestones as set forth in the Plan. On November 28, 2023, the Company received a written notice from the Nasdaq Staff which described its determination that the Company had not regained compliance with the Minimum Equity Requirement within the Plan period. On December 5, 2023, the Company requested a hearing, which was held on March 5, 2024 (the ‘Hearing’), staying any delisting pending the issuance of the Panel’s decision. At the Hearing, the Company presented a comprehensive compliance plan to regain compliance to the Nasdaq Panel and received the Panel Decision regarding the Nasdaq Listing Rules on March 20, 2024. Duyuru • Mar 08
Venus Concept Inc. announced that it has received CAD 1.095782 million in funding On March 7, 2024, Venus Concept Inc. closed the transaction. The transaction included participation from two investors. Duyuru • Feb 28
Venus Concept Inc. has completed a Follow-on Equity Offering in the amount of $1.198001 million. Venus Concept Inc. has completed a Follow-on Equity Offering in the amount of $1.198001 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 817,748
Price\Range: $1.465
Transaction Features: Registered Direct Offering Duyuru • Feb 21
Venus Concept Inc. to Report Q4, 2023 Results on Apr 01, 2024 Venus Concept Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 01, 2024 Duyuru • Jan 19
Venus Concept Inc. announced that it has received CAD 2 million in funding from Essex Woodlands Management, Inc. and another investor Venus Concept Inc. announced a private placement of secured convertible notes for an aggregate principal amount of CAD 2 million on January 19, 2024. The transaction included participation from returning investor Essex Woodlands Management, Inc. and and one of its affiliates. The convertible notes have a maturity date of December 9, 2025 and an annual interest rate of 90-day Adjusted SOFR + 8.5% that is payable in kind on a quarterly basis. The notes are convertible at any time into shares at an initial conversion price of CAD 1.251 per share, subject to adjustment. Duyuru • Dec 02
Nasdaq Staff Advises Venus Concept's Securities To Be Delisted At Opening of Business on December 7, 2023, Unless Company Timely Requests Hearing Before Nasdaq Hearings Panel As previously disclosed, on May 31, 2023, Venus Concept Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq Staff”) stating that the stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing under Listing Rule 5550(b)(1) (“Minimum Equity Requirement”). On July 17, 2023, the Company submitted to the Nasdaq Staff a plan to regain compliance with the Minimum Equity Requirement (the "Plan"). On July 28, 2023, the Nasdaq Staff granted an extension until November 27, 2023 to evidence compliance with the Minimum Equity Requirement, conditioned upon the Company’s achievement of certain milestones as set in the Plan. On November 28, 2023, the Company received a written notice from the Nasdaq Staff which described its determination that the Company had not regained compliance with the Minimum Equity Requirement within the Plan period. As a result, the Nasdaq Staff advised the Company that its securities will be delisted at the opening of business on December 7, 2023, unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the "Panel”). Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. Pursuant to the Nasdaq Listing Rules, the Panel is authorized to grant, where it deems appropriate, an additional extension period not to exceed May 28, 2024. The Company remains committed to taking all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. Reported Earnings • Nov 17
Third quarter 2023 earnings: EPS misses analyst expectations Third quarter 2023 results: US$1.64 loss per share (improved from US$3.36 loss in 3Q 2022). Revenue: US$17.6m (down 18% from 3Q 2022). Net loss: US$9.07m (loss narrowed 38% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.8%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Duyuru • Nov 17
Venus Concept Inc. Provides Earnings Guidance for the Twelve Months Ending December 31, 2023 Venus Concept Inc. provided earnings guidance for the twelve months ending December 31, 2023. For the period, company expected total revenue to be in range of $80.0 million to $82.0 million, compared to total revenue of $99.5 million for the twelve months ended December 31, 2022. Duyuru • Nov 02
Venus Concept Inc. Launches Venus Versa Pro, its New Multi-Application Platform for Face and Body Treatments Venus Concept Inc. announced the commercial launch of its new multi-application platform Venus Versa Pro in the United States. Venus Versa Pro supports 10 different applicators that can be used individually or in combination to target a wide range of aesthetic conditions, including skin texture, acne vulgaris, vascular and pigmented lesions, facial wrinkles and many more. Leveraging the company’s broad portfolio of innovative technologies, Venus Versa Pro incorporates the latest advancements of the company's Venus VivaMD device, allowing enhanced ablation and coagulation for deeper skin remodeling and optimal skin resurfacing results. Practitioners can also take advantage of the device’s multi-application approach, offering the unique Tribella treatment, which utilizes the company’s proprietary (MP)2 technology, as well as IPL and NanoFractional RF technologies for complete rejuvenation. Full commercial launch of Venus Versa Pro begins on November 1, 2023 with systems broadly available across the United States. Duyuru • Oct 10
Venus Concept Inc. to Report Q3, 2023 Results on Nov 14, 2023 Venus Concept Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2023 Major Estimate Revision • Oct 06
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$90.5m to US$80.7m. Forecast losses increased from -US$5.17 to -US$5.74 per share. Medical Equipment industry in the US expected to see average net income growth of 24% next year. Consensus price target down from US$13.00 to US$11.50. Share price rose 7.7% to US$2.11 over the past week. Duyuru • Sep 15
Venus Concept Inc. Receives 510(k) Clearance for the Venus Versa Pro System Venus Concept Inc. announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its Venus Versa Pro System, the Company’s new multi-application platform, for a variety of aesthetic and cosmetic procedures. Venus Versa is a modular system based on a multi-application approach. It is customizable and upgradable and offers the most in-demand aesthetic treatments by supporting 10 optional applicators which utilize Venus Concept’s (MP)2, IPL and NanoFractional RF technologies. Designed as a modular platform, the Venus Versa can be configured to best suit any practice’s needs with the ability to add additional applications as the practice grows or changes. The all new Venus Versa Pro System expands on the already comprehensive Venus Versa platform by incorporating proprietary advances in NanoFractional RF technologies from its dedicated skin resurfacing system, Venus VivaMD, providing higher power and deeper skin penetration for optimal results. New Risk • Aug 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.51m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Negative equity (-US$5.5m). Market cap is less than US$10m (US$9.51m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$21m net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). New Risk • Aug 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Negative equity (-US$5.5m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$25m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (US$10.5m market cap). Reported Earnings • Aug 15
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: US$1.35 loss per share (improved from US$2.47 loss in 2Q 2022). Revenue: US$20.1m (down 26% from 2Q 2022). Net loss: US$7.41m (loss narrowed 30% from 2Q 2022). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Board Change • Aug 01
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Member of Advisory Board Eric Bernstein was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jul 14
Venus Concept Inc. Announces Executive Changes Venus Concept Inc. announced the establishment of a medical advisory board for AI.ME, its next generation robotic platform. The medical advisory board is composed of six leading practicing physicians: Dr. Glynis Ablon, MD, FAAD. – Dr. Ablon is a board-certified dermatologist and cosmetic surgeon. Dr. Ablon is an Associate Clinical Professor at UCLA, practicing at both UCLA and LCMH. She is a Fellow of the American Academy of Dermatology, American Society for Laser Medicine and Surgery, and American Society for Dermatologic Surgery. Dr. Ablon is the owner and medical director of Ablon Skin Institute and Research Center, a boutique research center, actively performing over 60 clinical trials. Dr. Macrene Alexiades, MD, PhD – Dr. Alexiades is a Fellow of the American Academy of Dermatology and American Society for Laser Medicine (ASLMS) and Surgery and a Goldman Circle Member. She has achieved the rare status of Double Board-Certification in Dermatology in the European Union as well as the U.S. Dr. Alexiades is also an Associate Clinical Professor, Yale University and Founder & Director, Dermatology & Laser Surgery Center of New York. Dr. Eric Bernstein, MD, MSE – Dr. Bernstein is a dermatologist and researcher who has published extensively on the molecular basis of photoaging and the dermatologic uses of energy-based devices. He holds numerous US and international patents. Dr. Bernstein is past president of the ASLMS, is a director for the ASDS, and is Clinical Professor of Dermatology Perelman School of medicine at the University of Pennsylvania and Adjunct Professor of Dermatology at Temple University School of Medicine. Dr. James Chao, MD, FASC - Dr. Chao is board certified by the American Board of Plastic Surgery and is a Fellow of the American College of Surgeons. He is a member of the American Society of Plastic Surgeons, the American Society for Aesthetic Plastic Surgery, the American Society of Reconstructive Microsurgery and was previously the President of the San Diego Plastic Surgery Society. Dr. Chao serves as plastic and hand surgeon for the San Diego Chargers professional football team and is the recipient of numerous prestigious state and national research awards. In addition, he holds multiple patents of novel devices for plastic and hand surgery. Dr. Mitchel Goldman, MD – Dr. Goldman is a past president of the American Society for Dermatologic Surgery, the founder and past president of the American College of Phlebology, and Voted #1 Cosmetic Dermatologist in the USA by Newsweek in 2022 and 2023. He is the director of the American Society for Dermatologic Surgery Fellowship Program (which he conceived in 2013) and has hospital affiliations with Scripps Memorial Hospital in La Jolla, California. Dr. Gilly Munavalli MD, MHS, FACMS – Dr. Munavalli serves as a Clinical Assistant Professor at the Wake Forest University School of Medicine – Department of Dermatology and a Cosmetic Dermatologic Surgery Fellowship Director for the ASDS. He is founder and owner of Dermatology, Laser, and Vein Specialists of the Carolinas in Charlotte, NC, where has been in private practice for almost 20 years. This diverse team of dermatologists and plastic surgeons, all of whom have extensive clinical experience in aesthetic treatments and authored numerous publications in top peer-reviewed journals, will play an instrumental role in defining AI.ME's commercialization strategy. Duyuru • Jul 06
Venus Concept Inc. to Report Q2, 2023 Results on Aug 14, 2023 Venus Concept Inc. announced that they will report Q2, 2023 results on Aug 14, 2023 Major Estimate Revision • May 22
Consensus EPS estimates upgraded to US$4.88 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -US$5.85 to -US$4.88 per share. Revenue forecast steady at US$91.9m. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$24.00 to US$13.00. Share price fell 27% to US$2.37 over the past week. Duyuru • May 17
Venus Concept Inc. announced that it expects to receive $9 million in funding from Essex Woodlands Management, Inc. Venus Concept Inc. announced that it has entered into a security purchase agreements EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P a fund managed by Essex Woodlands Management, Inc. for private placement of senior convertible preferred stock of $9,000,000 on May 15, 2023. The company will receive investment in multiple tranches. The transaction is subject to a minimum aggregate purchase amount of $500,000 in each tranche. The Senior Preferred Stock will be convertible into shares of common stock on a 1 for 2.6667 basis at the option of the Investors at any time or the company within 30 days following the occurrence of specified trigger events. The terms of the Senior Preferred Stock are further described below under Item 5.03 of this Current Report on Form 8-K. The company will issue securities pursuant to exemption provided under exemptions provided by Section 4(a)(2) of Securities Act of 1933 and Regulation D. The sales of Senior Preferred Stock in the Private Placement are purely discretionary and must be approved by both the Company and the Investors. The transaction is expected to close till December 31, 2025.
On the same day, the company issued 280,899 Senior Preferred Stock at a price of $7.12 per share for an aggregate purchase price of $2,000,000. Price Target Changed • May 17
Price target decreased by 10% to US$22.50 Down from US$25.00, the current price target is an average from 2 analysts. New target price is 692% above last closing price of US$2.84. Stock is down 76% over the past year. The company is forecast to post a net loss per share of US$4.83 next year compared to a net loss per share of US$9.94 last year. Duyuru • May 16
Venus Concept Inc. Provides Revenue Guidance for the Twelve Months Ending December 31, 2023 Venus Concept Inc. provided revenue guidance for the twelve months ending December 31, 2023. For the year, the company continues to expect total revenue in the range of $90.0 million to $95.0 million, representing a decrease in the range of approximately 9.5% to 4.5%, year-over-year, compared to total revenue of $99.5 million for the twelve months ended December 31, 2022. Reported Earnings • May 16
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$1.85 loss per share. Revenue: US$20.5m (down 22% from 1Q 2022). Net loss: US$9.66m (loss widened 12% from 1Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Reported Earnings • Mar 29
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Full year 2022 results: US$0.66 loss per share (further deteriorated from US$0.42 loss in FY 2021). Revenue: US$99.5m (down 5.8% from FY 2021). Net loss: US$43.7m (loss widened 90% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. 